Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 1
2018 1
2019 1
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K, Varas L, Deronic A, Nyesiga B, Sundstedt A, Ljung L, Sakellariou C, Werchau D, Thagesson M, Gomez Jimenez D, Greiff L, Celander M, Smedenfors K, Rosén A, Bölükbas D, Carlsson F, Levin M, Säll A, von Schantz L, Lindstedt M, Ellmark P. Hägerbrand K, et al. J Immunother Cancer. 2022 Nov;10(11):e005018. doi: 10.1136/jitc-2022-005018. J Immunother Cancer. 2022. PMID: 36323431 Free PMC article.
CD103+CD11b+ mucosal classical dendritic cells initiate long-term switched antibody responses to flagellin.
Flores-Langarica A, Müller Luda K, Persson EK, Cook CN, Bobat S, Marshall JL, Dahlgren MW, Hägerbrand K, Toellner KM, Goodall MD, Withers DR, Henderson IR, Johansson Lindbom B, Cunningham AF, Agace WW. Flores-Langarica A, et al. Among authors: hagerbrand k. Mucosal Immunol. 2018 May;11(3):681-692. doi: 10.1038/mi.2017.105. Epub 2017 Dec 20. Mucosal Immunol. 2018. PMID: 29346347 Free PMC article.
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody.
Andersson H, Sobti A, Jimenez DG, de Coaña YP, Ambarkhane SV, Hägerbrand K, Smith KE, Lindstedt M, Ellmark P. Andersson H, et al. Among authors: hagerbrand k. Cells. 2023 Sep 27;12(19):2365. doi: 10.3390/cells12192365. Cells. 2023. PMID: 37830579 Free PMC article. Clinical Trial.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P. Kvarnhammar AM, et al. Among authors: hagerbrand k. J Immunother Cancer. 2019 Apr 11;7(1):103. doi: 10.1186/s40425-019-0570-8. J Immunother Cancer. 2019. PMID: 30975201 Free PMC article.